Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and ...

There appears to be growing frustration about FDA Commissioner Marty Makary’s management style within the highest levels of ...

Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, ...

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...